9 assets in Chronic Granulomatous Disease

Therapeutic assets addressing Chronic Granulomatous Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Thiotepa Chronic Granulomatous Disease	University of Florida	P2	BB (64)
Alemtuzumab Chronic Granulomatous Disease	Paul Szabolcs	P2	CCC (53)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Chronic Granulomatous Disease	Paul Szabolcs	P2	CCC (53)
Cyclophosphamide Chronic Granulomatous Disease	Roswell Park Cancer Institute	P2	CCC (53)
Fludarabine Chronic Granulomatous Disease	Paul Szabolcs	P2	CCC (53)
Melphalan Chronic Granulomatous Disease	Paul Szabolcs	P2	CCC (53)
cd3/cd19 negative allogeneic hematopoietic stem cells Chronic Granulomatous Disease	Paul Szabolcs	P1/2	CCC (48)
Busulfanum Chronic Granulomatous Disease	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Mesna Chronic Granulomatous Disease	Masonic Cancer Center, University of Minnesota	N/A	D (30)